-

Simulations Plus to Present at Raymond James 44th Annual Institutional Investors Conference

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be presenting at the Raymond James & Associates’ 44th Annual Institutional Investors Conference, scheduled for March 5-8, 2023, at the JW Marriott Grande Lakes in Orlando, Florida.

Shawn O’Connor, chief executive officer, will present on Tuesday, March 7, 2023, at 1:40 p.m. Eastern Time. In addition, Mr. O’Connor will be available to host one-on-one meetings throughout the day. The live webcast and slide presentation will be available via this link and on the Investors page of the Simulations Plus website where it will also be available for replay after the event.

The conference is by invitation only, so to attend the conference or request a one-on-one meeting, please contact your Raymond James representative. For more information about the Raymond James Institutional Investors Conference, please visit the Raymond James website or contact Brian Siegel from Hayden IR at brian@haydenir.com.

About Simulations Plus

Serving clients worldwide for more than 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on Twitter | LinkedIn.

Environmental, Social, and Governance (ESG)

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our ESG Report

Contacts

Simulations Plus Investor Relations
Ms. Renee Bouche
661-723-7723
renee.bouche@simulations-plus.com

Hayden IR
Mr. Brian Siegel
(346) 396-8696
brian@haydenir.com

Industry:

Simulations Plus, Inc.

NASDAQ:SLP
Release Summary
Simulations Plus will present at the Raymond James Institutional Investors Conference on March 7, 2023, at the JW Marriott Grande Lakes in Orlando, FL
Release Versions
English

Contacts

Simulations Plus Investor Relations
Ms. Renee Bouche
661-723-7723
renee.bouche@simulations-plus.com

Hayden IR
Mr. Brian Siegel
(346) 396-8696
brian@haydenir.com

Social Media Profiles
Simulations Plus on LinkedIn
Simulations Plus on Twitter
More News From Simulations Plus, Inc.

Simulations Plus Announces Funded Partnership with Global Pharmaceutical Company to Advance AI-Enabled QSP Model Development with Turin

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a funded partnership with a global large pharmaceutical company to apply Turin, its AI-enabled scientific engine for quantitative systems pharmacology (QSP), within an active therapeutic development program. The collaboration will evaluate how AI-enabled...

Simulations Plus Announces Completion of Acquisition by Altaris

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the completion of its acquisition by affiliates of Altaris, LLC ("Altaris"), an investment firm focused exclusively on the healthcare industry.The transaction was originally announced on June 16, 2026. At the effective time of the merger each Simulations...

Simulations Plus Expands FDA Adoption of ADMET Predictor® with New Licenses for the Cosmetics Regulatory Science Branch

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that the U.S. Food and Drug Administration’s (FDA) Cosmetics Regulatory Science Branch has licensed ADMET Predictor® to support its computational research for modern cosmetic safety assessment. The contract expands the use of Simulations Plus technology...
Back to Newsroom